PDCD1 and hepatocellular carcinoma: Two PD-1 inhibitors, nivolumab and pembrolizumab, have been approved by the FDA for HCC after treatment failure on sorafenib based on two phase II trials, the Checkmate-040 study and the Keynote‐224 trial, respectively 137, 138.